Welcome to your Saturday Biotech & Pharma Stock Market Recap

What’s to be covered in this hallowed scroll:

1. Overview of the biotech & pharma stocks that had the best & worst weeks (as measured by % change in price)

2. We’ll give you a calendar of whose announcing earnings in the upcoming week - and if they’re before the markets open (BMO) or after markets close (AMC).

3. One more thing we’ll have in future weeks - a recap of the more notable earnings calls the week previous.

Lastly - all three of the above will have sub-sections divided by:

1. Biotechnology (life sciences and the like)

2. Drug Manufacturers - General (this one includes big pharma)

3. Drug Manufacturers - Specialty and Pharma (everyone else that makes drugs, and then some)

And last thing - everything is in USD unless otherwise stated!

This weekend edition is a new feature at TLDR Biotech, so I’d love to get your feedback.

(You can also reach out to me on LinkedIn)

ENJOYING THESE NEWSLETTERS?
Consider an optional paid subscription.

TLDR Biotech is currently a one-person show that works full-time to put together these compilations and related content.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

Biotechnology

For the winners - Longeveron (LGVN) had a incredible week due to positive interim Ph2 results, and same goes for Avidity Bioscience (RNA) on “unprecedented” Ph1/2 results.

Though for the smaller-priced winners, like BioRestorative Therapies (BRTX), the mere whiff of a licensing negotiation sends the stock soaring.

For the losers - sometimes it has nothing to do with clinical data, and that’s the case for Tonix Pharmaceuticals (TNXP) that dropped due to a public offering on the heels of reverse stock split just the other week.

And sometimes your name can’t save you - which looks to the case for Gain Therapeutics (GANX), which also dropped on news of a public offering.

Upcoming Biotechnology Earnings Calls

No earnings call next week for this group!

Instead, why not learn about the drama-ridden reality TV show that was the discovery of DNA’s double-helix?

AFFILIATE
Finviz: ✨Financial Visualizations🤩

I’m using Finviz to put together these compilations - it’s the easiest way to visualize and assess multiple stocks within the same industry (like within biotech).

If this is down your alley, you can check it out for free using my Affiliate link.

Drug Manufacturers - General

Scilex (SCLX) skyrocketed this week on a double-whammy of good news; their third commercial product begins it’s roll-out, and they announced some less than PAINful Ph3 news.

On the other hand, Sanofi didn’t have a great week (and yes, that’s an exact YTD change -7.00), potentially due to flu vaccine supply issues (and increased competition in the flu space).

Though this happened earlier than the above news, short interest in Sanofi also grew dramatically last month.

Upcoming Drug Manufacturers - General Earnings Calls

No earnings next week for this week group!

Instead, why not learn about some the more outlandish beliefs help by some Nobel Prize winners?

Drug Manufacturers - Specialty & Generic

For the winners - usually this category has some major upswings, but it’s been a pretty moderate week for the winners here - nothing significant to report for any of them (even for Journey Medical (DERM)).

For the losers - considering the stock price of the top 4 losers, it might have been a light breeze that sent them down double-digits.

Though for the only non-penny stock on the loser list SIGA Technologies (SIGA), it’s a little more material - despite their collaboration announcement, a continued earnings decline might be spooking investors.

Upcoming Drug Manufacturers - Specialty & Generic Earnings Calls

For all the 🌲 fans out there, Aurora Cannabis (ACB) is reporting earning next week. Though Mary Jane isn’t the strongest investment, as one analyst article put it, “the benefits of choosing from some of the most beaten-down market segments like cannabis is that even a little bit of market positivity can lead to solid profits.”

That’s all for now - go enjoy your weekend!

TLDR Biotech wants to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

And if you like this newsletter and think a friend or colleague would benefit, please share this with them! ♻️

Want to sponsor this newsletter and reach an audience of 500+ biotech and pharma professionals? Reach us here. 👍

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here